Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
Abstract
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
참고문헌 (5)
- Gowda RM, "Therapeutics of platelet glycoprotein IIb", IIIa receptor antagonism, 2004, pp.11, 302~307
- Midei MG, "Clinical outcomes comparing eptifibatide and abciximab in ST elevation acute myocardial infarction patients undergoing percutaneous coronary intervention", Cardiology, 107, pp.172~177 (2006)
- Merlini PA, "Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting", Circulation, 109, pp.2203~2206 (2004)
- Konstance R, "Incidence and predictors of major vascular complications after percutaneous coronary intervention in the glycoprotein IIb", IIIa platelet inhibitor era, 2004, pp.17, 65~70
- van Mieghen C, "Left ventricular hematoma and cardiac tamponade complicating percutaneous coronary intervention using IIb", IIIa receptor antagonists, 2003, pp.16, 381~384